A novel chronic hepatitis B mouse model with immune activation and liver fibrosis.

ABSTRACT: As one of the key features of the immune active (IA) phase (HBeAg-positive) in chronic hepatitis B (CHB), liver fibrosis (LF) is a critical treatable stage to avoid progressing to hepatocellular carcinoma (HCC). There is an urgent need to establish mouse models that mimic CHB during this phase to clarify the mechanisms underlying hepatitis B virus (HBV) clearance and liver injury, as well as to facilitate therapy development. In the present work, we introduce a novel HBV mouse model via injections of porcine serum (PS, an immunological liver injury inducer), in combination with hydrodynamic injection of pAAV-HBV1.2 plasmid. The (pAAV-HBV1.2+PS BALB/c) mouse model we developed exhibits the typical features of the IA phase in CHB, including high/intermediate serum HBsAg levels, positive HBeA

SUBMITTER: Wu D 

PROVIDER: S-EPMC12419765 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature